Health / Medical Topics

    Anti-CD27 Monoclonal Antibody CDX-1127

    A human agonistic monoclonal antibody (MoAb) specific for CD27, with potential immunostimulating and antineoplastic activity. Upon administration of CDX-1127, this MoAb binds to CD27 and may potentiate the immune response by increasing the cytotoxic T-lymphocyte (CTL) response against CD27-expressing tumor cells. This may lead to growth inhibition of CD27-expressing tumor cells. In addition, this agent may increase the proliferation and activation of antigen-specific T lymphocytes upon co-administration of TAA-containing vaccines, such as dendritic cell vaccines. CD27, a co-stimulatory molecule and member of the tumor necrosis factor family overexpressed in certain tumor cell types, is constitutively expressed on mature T-lymphocytes, memory B cells and natural killer cells and plays an important role in NK cell mediated cytolytic activity and T and B lymphocyte proliferation and activation. (NCI Thesaurus)




    YOU MAY ALSO LIKE

    Any monoclonal antibody directed against the alpha subunit of the human interleukin 2 receptor.
    An antibody-drug conjugate (ADC) composed of MCDT2219A , a humanized IgG1 anti-CD22 monoclonal antibody covalently linked, via a protease-cleavable peptide linker, to…
    A monoclonal antibody linked to a toxic substance. It is being studied in the treatment of some types of B-cell cancer. Anti-CD22…
    A monoclonal antibody linked to a toxic substance. It is being studied in the treatment of some types of B-cell cancer. Anti-CD22…
    A humanized monoclonal antibody directed against the human immunosuppressive molecule CD200 (OX-2) with potential immunomodulating and antineoplastic activities. Anti-CD200 monoclonal antibody ALXN6000…
    A preparation of autologous blood T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) consisting of an anti-CD20…

    © 1991-2023 The Titi Tudorancea Bulletin | Titi Tudorancea® is a Registered Trademark | Terms of use and privacy policy
    Contact